Saitama

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Endometrial cancer3 trials
• Head and neck cancer2 trials
• ANCA-associated vasculitis1 trial
• Chronic kidney disease1 trial
• Lung cancer1 trial
• Osteoarthritis1 trial
• Ovarian cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials
• Phase 24 trials

Status

• Active, not recruiting5 trials
• Recruiting4 trials
• Completed1 trial
• Terminated1 trial

Lead sponsor

• GlaxoSmithKline11 trials

Running trials

• Recruiting

  A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

  NCT07684599· Phase 3· GlaxoSmithKline· Source

  Contact: Kosei Hasegawa (principal investigator)

• Recruiting

  A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

  NCT07286266· Phase 3· GlaxoSmithKline· Source

  Contact: Kosei Hasegawa (principal investigator)

• Recruiting

  A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

  NCT07286331· Phase 3· GlaxoSmithKline· Source

  Contact: Kosei Hasegawa (principal investigator)

• Active, not recruiting

  A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

  NCT06317311· Phase 2· GlaxoSmithKline· Source

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Tomoko Yamazaki (principal investigator)

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

  NCT06062420· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

  NCT05565378· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

  NCT05263934· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer2 recruiting
• Head and neck cancer1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Terminated

  A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

  NCT05838742· Phase 2· GlaxoSmithKline· Source

• Completed

  Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)

  NCT05682326· Phase 3· GlaxoSmithKline· Source